Acha V, Mestre-Ferrandiz J. Translating European regulatory approval into healthcare uptake for biosimilars: the second translational gap. TASM. 2017;29(3):263–75. https://doi.org/10.1080/09537325.2017.1285396.

Article  Google Scholar 

Mestre-Ferrandiz J, Towse A, Berdud M. Biosimilars: how can payers get long-term savings? Pharmacoeconomics. 2016;34(6):609–16. https://doi.org/10.1007/s40273-015-0380-x.

Article  PubMed  PubMed Central  Google Scholar 

Scott Morton FM, Stern AD, Stern S. The impact of the entry of biosimilars: evidence from Europe. J Regul Econ. 2018;53(1):173–210. https://doi.org/10.1007/21151-018-9630-3.

Article  Google Scholar 

Moorkens E, Vulto AG, Huys I, et al. Policies for biosimilar uptake in Europe: an overview. PLoS ONE. 2017;12(12): e0190147. https://doi.org/10.1371/journal.pone.0190147.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Moorkens E, Jonker Exler C, Huys I, et al. Overcoming barriers to the market access of biosimilars in the European Union: the case of biosimilar monoclonal antibodies. Front Pharmacol. 2016;7:193. https://doi.org/10.3389/fphar.2016.00193.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Phipps-Taylor M, Shortell SM. More than money: motivating physician behavior change in accountable care organizations. Milbank Q. 2016;94(4):832–61. https://doi.org/10.1111/1468-0009.12230.

Article  PubMed  PubMed Central  Google Scholar 

Gaynor M, Rebitzer JB, Taylor LJ. Physician incentives in health maintenance organisations. J Polit Econ. 2004;112(4):915–31. https://doi.org/10.1086/421172.

Article  Google Scholar 

Lazear E, Gibbs M. Personnel economics in practice. 1st ed. Wiley; 2015, passim.

Milkovich GT, Newman J, Gerhart B. Compensation. 11th ed. McGraw-Hill International; 2013, passim.

Incentivisation. In: Wikipedia [Internet]. San Francisco (CA): Wikimedia Foundation, Inc.; 2006 [updated 28 May 2024; cited 2 Jun 2025]. Available from: https://en.wikipedia.org/wiki/Incentivisation.

Lubarsky DA, French MT, Gitlow HS, Rosen LF, Ullmann SG. Why money alone can’t (always) ‘nudge’ physicians: the role of behavioral economics in the design of physician incentives. Anesthesiol. 2019;130(1):154–70. https://doi.org/10.1097/ALN.0000000000002373.

Article  Google Scholar 

Tak HJ, Curlin FA, Yoon JD. Association of intrinsic motivating factors and markers of physician well-being: a national physician survey. J Gen Intern Med. 2017;32(7):739–46. https://doi.org/10.1007/s11606-017-3997-y.

Article  PubMed  PubMed Central  Google Scholar 

Berdud M, Cabasés JM, Nieto J. Incentives and intrinsic motivation in healthcare. Gac Sanit. 2016;30:408–14. https://doi.org/10.1016/j.gaceta.2016.04.013.

Article  PubMed  Google Scholar 

Flodgren G, Eccles MP, Shepperd S, et al. An overview of reviews evaluating the effectiveness of financial incentives in changing healthcare professional behaviours and patient outcomes. Cochrane Database Syst Rev. 2011;7:CD009255. https://doi.org/10.1002/14651858.CD009255.

Article  Google Scholar 

Mandavia R, Mehta N, Schilder A, Mossialos E. Effectiveness of UK provider financial incentives on quality of care: a systematic review. Br J Gen Pract. 2017;67(664):e800–15. https://doi.org/10.3399/bjgp17X693149.

Article  PubMed  PubMed Central  Google Scholar 

Lazear EP. Compensation and incentives in the workplace. J Econ Perspect. 2018;32(3):195–214. https://doi.org/10.1257/jep.32.3.195.

Article  Google Scholar 

Lobo F. Análisis y práctica de las políticas de precios y financiación de los medicamentos. Springer Healthcare; 2016. https://e-archivo.uc3m.es/handle/10016/26086.

Dylst P, Vulto A, Simoens S. Demand-side policies to encourage the use of generic medicines: an overview. Expert Rev Pharmacoecon Outcomes Res. 2013;13(1):59–72. https://doi.org/10.1586/erp.12.83.

Article  PubMed  Google Scholar 

Rashidian A, Omidvari AH, Vali Y, et al. Pharmaceutical policies: effects of financial incentives for prescribers. Cochrane Database Syst Rev. 2015;8:CD006731. https://doi.org/10.1002/14651858.CD006731.pub2.

Article  Google Scholar 

Lobo F, del Río I. Gestión clínica, incentivos y biosimilares. Ediciones Díaz de Santos; 2020. https://www.editdiazdesantos.com/wwwdat/pdf/9788490523001.pdf.

Lobo F, Río-Álvarez I. Barriers to biosimilar prescribing incentives in the context of clinical governance in Spain. Pharmaceuticals. 2021;14(3):283. https://doi.org/10.3390/ph14030283.

Article  PubMed  PubMed Central  Google Scholar 

Tricco AC, Lille E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018. https://doi.org/10.7326/M18-0850.

Article  PubMed  Google Scholar 

Munn Z, Pollock D, Khalil H, et al. What are scoping reviews? Providing a formal definition of scoping reviews as a type of evidence synthesis. JBI Evid Synth. 2022;20(4):950–2. https://doi.org/10.11124/JBIES-21-00483.

Article  PubMed  Google Scholar 

University of Southern Australia. Guides. Overview of scoping reviews. https://guides.library.unisa.edu.au/ScopingReviews/ScopingReviewOverview. Downloaded Nov. 27 2024.

Farfan-Portet M, Gerkens S, Lepage-Nefkens I, Vinck I, Hulstaert F. Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures? Eur J Health Econ. 2014;15(3):223–8. https://doi.org/10.1007/20198-013-0538-4.

Article  PubMed  Google Scholar 

Simoens S, Le Pen C, Boone N, et al. How to realize the potential of off-patent biologicals and biosimilars in Europe? Guidance to policymakers. Generics and Biosimilars Initiative Journal. 2018;7(2):70-4. https://gabi-journal.net/how-to-realize-the-potential-of-off-patent-biologicals-and-biosimilars-in-europe-guidance-to-policymakers.html.

Barbier L, Simoens S, Vulto AG, Huys I. European stakeholder learnings regarding biosimilars: part II-improving biosimilar use in clinical practice. BioDrugs. 2020;34(6):797–808. https://doi.org/10.1007/s40259-020-00440-z.

Article  PubMed  PubMed Central  Google Scholar 

Rémuzat C, Dorey J, Cristeau O, Ionescu D, Radière G, Toumi M. Key drivers for market penetration of biosimilars in Europe. J Mark Access Health Policy. 2017;5(1):1272308. https://doi.org/10.1080/20016689.2016.1272308.

Article  PubMed  PubMed Central  Google Scholar 

Rémuzat C, Kapuśniak A, Caban A, et al. Supply-side and demand-side policies for biosimilars: an overview in 10 European member states. J Mark Access Health Policy. 2017;5(1):1307315. https://doi.org/10.1080/20016689.2017.1307315.

Article  PubMed  PubMed Central  Google Scholar 

Bocquet F, Loubière A, Fusier I, Cordonnier AL, Paubel P. Competition between biosimilars and patented biologics: learning from European and Japanese experience. Pharmacoeconomics. 2016;34(11):1173–86. https://doi.org/10.1007/s40273-016-0428-6.

Article  PubMed  Google Scholar 

Gaffney A, Cadi-Tazi A, Ribeiro A. Payer and physician dynamics surrounding biosimilar access in the EU. Value Health. 2019;22:S427. https://doi.org/10.1016/j.jval.2019.09.161.

Article  Google Scholar 

Moorkens E, Simoens S, Troein P, Declerck P, Vulto AG, Huys I. Different policy measures and practices between Swedish counties influence market dynamics: part 1—biosimilar and originator infliximab in the hospital setting. BioDrugs. 2019;33(3):285–97. https://doi.org/10.1007/s40259-019-00345-6.

Article  PubMed  PubMed Central  Google Scholar 

Moorkens E, Simoens S, Troein P, Declerck P, Vulto AG, Huys I. Different policy measures and practices between Swedish counties influence market dynamics: part 2—biosimilar and originator etanercept in the outpatient setting. BioDrugs. 2019;33(3):299–306. https://doi.org/10.1007/s40259-019-00346-5.

Article  PubMed  PubMed Central  Google Scholar 

Lepage-Nefkens I, Gerkens S, Vinck I, et al. Barriers and opportunities for the uptake of biosimilar medicines in Belgium. 199. Brussels: KCE Health Services Research. 2013. https://belgica.kbr.be/BELGICA/detailstatic.aspx?RSC_BASE=SYRACUSE&RSC_DOCID=10113756&TITLE=barriers-and-opportunities-for-the-uptake-of-biosimilar-medicines-in-belgium&_lg=en-GB.

Dylst P, Vulto A, Simoens S. Barriers to the uptake of biosimilars and possible solutions: a Belgian case study. Pharmacoeconomics. 2014;32:681–91. https://doi.org/10.1007/s40273-014-0163-9.

Article  PubMed  Google Scholar 

Swartenbroekx N, Farfan-Portet MI, Espín J, Gerkens S. Incentives for market penetration of biosimilars in Belgium and in five European countries. J Pharm Belg. 2014;4:36–46. https://pubmed.ncbi.nlm.nih.gov/25562926/.

Bocquet F, Paubel P, Fusier, et al. Biosimilar versus patented erythropoietins: learning from 5 years of European and Japanese experience. Appl Health Econ Health Policy. 2015;13(1):47–59. https://doi.org/10.1007/s40258-014-0125-6.

Article  PubMed  Google Scholar 

Bocquet F, Paubel P, Fusier I, Cordonnier A, Le Pen C, Sinegre M. Biosimilar granulocyte colony-stimulating factor uptakes in the EU-5 markets: a descriptive analysis. Appl Health Econ Health Policy. 2014;12(3):315–26. https://doi.org/10.1007/s40258-014-0087-8.